• 1
    Okamura H, Tsutsui H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995; 378: 8891.
  • 2
    Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human IFN-gamma–inducing factor, expression in Escherichia coli and studies on the biologic activities of the protein. J Immunol. 1996; 156: 42744279.
  • 3
    Fukumoto H, Nishio M, Nishio K, et al. Interferon-gamma inducing factor gene transection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jpn J Cancer Res. 1997; 88: 501505.
  • 4
    Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol. 2001; 167: 16441653.
  • 5
    Margaret N, Xiuling X, Franck B, et al. A critical role for interleukin-18 in primary and memory effector responses to listeria monocytogenes that extends beyond its effects on interferon gamma production. J Exp Med. 2001; 194: 343354.
  • 6
    Ohisuki T, Micallef MJ, Tanimoto T, Ikeda M, Kurimot M. Interleukin-18 enhances fas ligand expression and induces apoptosis in fas-expressing human myelomonocytic KG-1 cells. Anticancer Res. 1997; 17: 32533258.
  • 7
    Takubo T, Kumura T, Nakao T, et al. Comparative study on complete remission rate and overall survival in three groups classified based on the serum interleukin-18 level in non-Hodgkin's lymphoma patients. Acta Haematol. 2000; 104: 220222.
  • 8
    Kawabata T, Lehikura T, Majima T, Seki S, Chochi K. Preoperative serum IL-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer. 2001; 92: 250255.
  • 9
    Ohshima H, Baitsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res. 1994; 305: 253264.
  • 10
    Thomsen L, Mikes D, Happerfield L, Bobrow L, Knowles R, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995; 72: 4144.
  • 11
    Coskun U, Ozenirler S, Sancak B, Bukan N. Serum and ascitic fluid nitrate levels in patients with cirrhosis. Clin Chim Acta. 2001; 306: 127132.
  • 12
    Chikano S, Sawada K, Shimoyama T, Kashiwamura S. IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut. 2000; 47: 779786.
  • 13
    Brennan P, Zaki G, Spedding A, Langdon J. Type II nitric oxide synthase expression correlates with lymph node status in oral squamous cell carcinoma. J Oral Pathol Med. 2001; 30: 129134.
  • 14
    Wang B, Xiong Q, Shi Q, Le X. Genetic disruption of host interferon-gamma drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase. Oncogene. 2001; 20: 69306937.
  • 15
    Green LC, Wagner DA, Glogowski J, Skipper PL, Whisnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and (15N) nitrate in biological fluids. Ann Biochem. 1982; 121: 131138.
  • 16
    Bories PN, Bories C. Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem. 1995; 4: 904907.
  • 17
    Taniguchi M, Nagaoka K, Kunikata T, et al. Characterization of antihuman interleukin-18 (IL-18) interferon-gamma–inducing factor (IGIF) mononclonal antibodies and their application in the measurement of human IL-18 by ELISA. J Immunol Methods. 1997; 206: 107113.
  • 18
    Molina R, Jo J, Zanon G, et al. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15-3. Br J Cancer. 1996; 7: 11261131.
  • 19
    Golab J. Interleukin 18-interferon gamma inducing factor: a novel player in tumour immunotherapy? Cytokine. 2000; 12: 332338.
  • 20
    Pages F, Berger A, Henglein B, et al. Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer. 1999; 84: 326330.
  • 21
    Udagawa N, Horwood NJ, Elliot J, et al. Interleukin-18 is produced by osteoblasts and acts via granulocyte/macrophage colony stimulating factor. J Exp Med. 1997; 185: 10051112.
  • 22
    Nakata A, Tsujimura T, Sugihara A, et al. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res. 1999; 19: 41314138.
  • 23
    Merendino RA, Gangemi S, Ruello A, et al. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int J Biol Markers. 2001; 16: 126129.
  • 24
    Kim Y, Talaninian J. Nitric oxide presents IL-1 beta and IFN-gamma–inducing factor (IL-18) release from macrophages by inhibiting caspase 1 (IL-1 beta converting enzyme). J Immunol. 1998; 161: 41224128.
  • 25
    Quian S, Qinghua Y, Bailiang W, Xiangdong L, Nasım A. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Res. 2000; 60: 25792583.
  • 26
    Cui S, Reicher JS, Mateo RB, Albino JE. Activated murine macrophage induces apoptosis in tumour cells through nitric oxide dependent or independent mechanisms. Cancer Res. 1994; 54: 24622467.
  • 27
    Martin JHJ, Alalami O, Van den Berg HW. Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence. Cancer Lett. 1999; 144: 6574.
  • 28
    MacRitchie AN, Jun SS, Chen Z, German Z, Yuhanna IS, Sherman TS. Estrogen up regulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res. 1997; 81: 355362.
  • 29
    Sylvie R, Lavent A, Genevieve J, Sophie K, Pascale L, Valerie S. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate and expression of progesterone receptors. Lab Invest. 1999; 79: 12151225.
  • 30
    Langrehr JM, Murase N, Markus PM, et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest. 1992; 90: 679683.
  • 31
    MacIntyre I, Zaidi M, Alam A, et al. Osteoclastic inhibition: an action of nitric oxide not mediated by cylic GMP. Proc Natl Acad Sci U S A. 1991; 88: 29362940.
  • 32
    Damoulis P, Hauschka P. Cytokines induce nitric oxide production in mouse osteoblasts. Biochem Biophys Res Commun. 1994; 201: 924931.
  • 33
    Rutger L, Chris V, Socrates E. Osteogenic compounds modulate cytokine-induced nitric oxide production in mouse osteoblast-like cells. J Pharmacol. 1999; 51: 14091414.
  • 34
    Iwasaki T, Hgashiyamo M, Kuriyamo K, Sasake A, Mukai M, Shinkas K. NG-nitro-L-arginine methyl ester inhibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model. Jpn. J Cancer Res. 1997; 88: 861866.